Does Anthem Cover Semaglutide (Wegovy)?

How Anthem Decides Whether to Cover Wegovy

Anthem does not apply one single national formulary to every member. Coverage depends on the specific plan type, the employer group contract (for employer-sponsored insurance), and the state in which the plan is issued. Some Anthem commercial PPO and HMO plans include Wegovy on Tier 4 or Tier 5 of their formulary with prior authorization; others exclude it completely.

Plan Types That Most Often Include Wegovy

Fully insured commercial plans regulated by state insurance departments are more likely to cover Wegovy than self-funded ERISA employer plans. Self-funded plans set their own drug lists, and obesity pharmacotherapy is one of the most commonly carved-out benefit categories. A 2023 KFF analysis found that only about 27% of large employer plans covered GLP-1 agonists for obesity (as opposed to diabetes), so the odds of coverage depend heavily on which category your employer falls into.

Medicare Part D plans are subject to a statutory exclusion for weight-loss drugs. The Treat and Reduce Obesity Act has been introduced in Congress repeatedly but has not yet passed as of 2025, so semaglutide for weight management alone remains non-covered under standard Medicare Part D. However, patients who also have type 2 diabetes may qualify for coverage of lower-dose semaglutide products (Ozempic 0.5 mg to 2 mg) under Part D, because that indication is not classified as a weight-loss drug [1].

Medicaid coverage varies by state. Some state Medicaid programs administered through Anthem (Anthem is a major Medicaid managed care organization in multiple states) do cover Wegovy; others do not. Checking the specific state Medicaid drug list is the only reliable method.

What the Anthem Medical Policy Actually Requires

For plans that do cover Wegovy, Anthem's clinical coverage guidelines generally mirror the FDA label and the 2023 American Association of Clinical Endocrinology (AACE) Comprehensive Type 2 Diabetes Management Algorithm guidance, which supports pharmacotherapy for obesity at BMI 30 or above, or BMI 27 or above with at least one weight-related comorbidity [2].

Typical Anthem prior-authorization criteria include:

• BMI <30 kg/m², or BMI <27 kg/m² with a documented comorbidity such as hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease
• A minimum 3- to 6-month trial of a structured diet and exercise program without adequate weight loss (usually defined as less than 5% body weight)
• Prescription written by or in consultation with a physician (some plans require an endocrinologist, bariatric specialist, or obesity medicine, certified physician)
• No active eating disorder diagnosis
• Not concurrently prescribed another weight-loss medication

These criteria align with FDA-approved labeling. The FDA label for Wegovy states it is indicated as an adjunct to a reduced-calorie diet and increased physical activity in adults with initial BMI of 30 kg/m² or greater, or 27 kg/m² or greater in the presence of at least one weight-related comorbid condition [3].

The Clinical Evidence Supporting Coverage Decisions

Insurance coverage policies follow clinical trial data. Understanding that data strengthens a prior-authorization request and helps clinicians write persuasive medical necessity letters.

STEP-1: The Weight-Loss Benchmark

The STEP-1 trial (N=1,961) published in the New England Journal of Medicine in 2021 randomized adults with obesity (BMI <30) to semaglutide 2.4 mg once weekly or placebo for 68 weeks. Participants receiving semaglutide achieved a mean body-weight reduction of 14.9% versus 2.4% with placebo (P<0.001) [4]. That magnitude of weight loss is comparable to outcomes seen with some bariatric surgical procedures in the short term.

SELECT: The Cardiovascular Case for Coverage

The SELECT trial (N=17,604), published in the New England Journal of Medicine in November 2023, enrolled adults with established cardiovascular disease and a BMI of 27 or greater who did not have diabetes. Semaglutide 2.4 mg reduced the composite endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 20% versus placebo over a mean follow-up of 33.3 months (HR 0.80; 95% CI 0.72 to 0.90; P<0.001) [5].

This cardiovascular mortality reduction is clinically significant for coverage arguments. A patient with established CVD who is denied Wegovy coverage is being denied a drug with a proven MACE reduction, not merely a cosmetic weight-loss agent. Physicians writing appeal letters for this patient population should cite SELECT explicitly.

STEP-5: Long-Term Durability

STEP-5 (N=304) followed patients for 104 weeks and found sustained mean weight loss of 15.2% in the semaglutide group versus 2.6% with placebo, confirming that the drug's effect is maintained beyond the first year of treatment [6]. This matters for coverage discussions about ongoing authorization renewals.

How to Get Prior Authorization Approved on the First Attempt

Anthem denies a substantial proportion of Wegovy prior-authorization requests on the first submission, usually because documentation is incomplete rather than because the patient is ineligible. A structured approach raises first-pass approval rates.

Step 1: Verify Your Specific Plan's Formulary

Before the prescriber submits anything, the patient or office staff should call the member services number on the back of the Anthem insurance card and ask three specific questions:

1. Is semaglutide 2.4 mg (Wegovy, NDC 00169-4930-11) covered on my plan's formulary?
2. If yes, what tier is it on, and what is the prior-authorization criteria document number?
3. If excluded, is there an exception process?

Anthem's online formulary search tool at anthem.com also allows drug-specific lookups by plan name.

Step 2: Gather Required Clinical Documentation

The prior-authorization packet should contain:

• Current height, weight, and BMI measurement with the date
• All relevant ICD-10 codes (E66.01 for morbid obesity, E66.09 for other obesity, E11 series for type 2 diabetes, I10 for hypertension, and so on)
• A dated note documenting the lifestyle-modification program with duration and outcome (weight change in kilograms or percentage)
• Any relevant lab results: HbA1c, fasting lipid panel, blood pressure readings
• A medical necessity statement referencing Anthem's own clinical coverage policy number

Step 3: Write a Targeted Medical Necessity Letter

The treating physician's letter should quote Anthem's own clinical policy language back to the reviewer and reference the SELECT and STEP-1 trial data directly. A letter that reads "patient has obesity and hypertension" is weaker than one that states: "This patient meets Anthem clinical policy criteria for semaglutide 2.4 mg. Per STEP-1 (N=1,961, NEJM 2021), semaglutide produces 14.9% mean weight loss versus 2.4% placebo, reducing cardiovascular risk factors. Per SELECT (N=17,604, NEJM 2023), semaglutide 2.4 mg reduces MACE by 20% in patients with established CVD and BMI <27, which this patient also carries." [4][5]

The Obesity Medicine Association recommends that physicians treating patients with obesity document the clinical rationale for pharmacotherapy using the same language found in the applicable insurance policy's medical necessity criteria [7].

What to Do When Anthem Denies Coverage

A denial is not a final answer. Federal law under the Affordable Care Act and most state laws give patients the right to an internal appeal and then an external independent review.

Internal Appeal

File within the timeframe printed on the denial letter (typically 180 days for commercial plans). The appeal should include:

• The original denial letter
• Updated clinical documentation
• A peer-reviewed literature summary (STEP-1, SELECT, STEP-5 are the primary references)
• A letter from the prescribing physician

Studies of insurance appeals across therapeutic areas consistently show that patients who submit appeals with complete clinical documentation are more likely to succeed than those who submit appeals with the same original paperwork [8].

External Independent Review

If the internal appeal fails, commercial plan members generally have the right to request an independent external review through their state's insurance commissioner or through the federal external review process administered under the ACA. The external reviewer is a neutral organization and is not employed by Anthem. External review decisions are binding on the insurer in most states.

Peer-to-Peer Review

The prescribing physician can request a peer-to-peer telephone review with the Anthem medical director assigned to the case. This conversation gives the clinician a direct opportunity to explain why the patient meets medical necessity criteria. Peer-to-peer reviews are time-limited (usually must be requested within 3 to 5 business days of denial), so the prescriber's office should act quickly.

Cost Without Coverage: What Patients Actually Pay

Without insurance coverage, Wegovy's wholesale acquisition cost (WAC) was approximately $1,349 per 28-day supply as of early 2024. This figure does not include pharmacy dispensing fees or any potential markup [9].

Novo Nordisk NovoCare Savings Program

Commercially insured patients who have coverage but face high cost-sharing may qualify for Novo Nordisk's savings card, which in some cases reduces monthly out-of-pocket cost to as little as $0 for up to 24 months. The program does not apply to patients covered by Medicare, Medicaid, or any other government-funded program [10]. Eligibility and terms change, so patients should verify current terms at novonordisk-us.com or by calling 1-833-NOVO-411.

Patient Assistance Program

Patients without any insurance coverage and with household incomes at or below 400% of the federal poverty level may qualify for free medication through the Novo Nordisk Patient Assistance Program. Applications are processed through NovoCare.

Compounded Semaglutide: A Temporary Option That Is Closing

During the FDA-declared shortage of semaglutide (which was in effect from 2022 through parts of 2024), certain FDA-registered 503A and 503B compounding pharmacies were permitted to compound semaglutide for individual patients. The FDA removed semaglutide from the shortage list in October 2024, which means compounding of semaglutide by most pharmacies is no longer permitted under federal law as of early 2025 [11]. Patients who were using compounded semaglutide should consult their prescriber about transitioning to the branded product or another FDA-approved option.

Alternatives If Wegovy Remains Uncovered

Several FDA-approved alternatives exist for weight management. Each has a different coverage profile, and some may be on Anthem's formulary even when Wegovy is not.

Tirzepatide (Zepbound)

The FDA approved tirzepatide 2.5 mg to 15 mg (Zepbound) for chronic weight management in November 2023. The SURMOUNT-1 trial (N=2,539) demonstrated mean weight loss of 20.9% at 72 weeks with tirzepatide 15 mg versus 3.1% with placebo [12]. Anthem coverage of Zepbound mirrors Wegovy coverage decisions at the plan level, but formulary placement differs. Eli Lilly launched a direct-to-consumer self-pay program (LillyDirect) at approximately $550 per month for some doses, which is notably below Wegovy's list price.

Liraglutide (Saxenda)

Liraglutide 3 mg daily (Saxenda), a once-daily GLP-1 receptor agonist, has been on the market since 2014. Some Anthem plans that have not yet added Wegovy to the formulary carry Saxenda on an older formulary tier. The SCALE Obesity and Prediabetes trial (N=3,731) showed a mean 8.0% weight loss with liraglutide 3 mg versus 2.6% with placebo at 56 weeks [13].

Phentermine/Topiramate Extended-Release (Qsymia)

This oral combination agent is substantially cheaper than GLP-1 injectables and may be covered under pharmacy benefits that exclude injectables. It is not appropriate for patients with cardiovascular disease or a history of certain psychiatric conditions.

Semaglutide for Type 2 Diabetes: A Different Coverage Path

Patients who have both obesity and type 2 diabetes face a more favorable coverage field. Ozempic (semaglutide 0.5 mg to 2 mg) is FDA-approved for type 2 diabetes management and cardiovascular risk reduction in adults with type 2 diabetes and established CVD [14]. Most Anthem commercial plans and Medicare Part D plans cover Ozempic for its diabetes indication. The SUSTAIN-6 trial (N=3,297) showed that semaglutide 0.5 mg and 1 mg reduced the composite of cardiovascular death, nonfatal MI, and nonfatal stroke by 26% compared with placebo in patients with type 2 diabetes (HR 0.74; 95% CI 0.58 to 0.95; P<0.001 for noninferiority) [15].

A patient prescribed Ozempic for diabetes who also loses weight is receiving a covered benefit. The trade-off is that the dose approved for diabetes management tops out at 2 mg weekly, while the obesity label for Wegovy goes to 2.4 mg weekly. Off-label use of higher-dose Ozempic for weight management is generally not covered and raises separate prescribing and liability considerations.

State-Level Mandates That May Affect Anthem Coverage

A growing number of states have passed or proposed obesity treatment mandate legislation requiring insurers to cover FDA-approved obesity pharmacotherapy. As of 2025, states including Illinois and several others have enacted laws requiring coverage of obesity drugs in fully insured plans. Because Anthem operates fully insured plans in multiple states, members in states with active mandates may have coverage regardless of what the base Anthem formulary says [16].

Self-funded ERISA plans, which cover roughly 60% of privately insured Americans, are exempt from state insurance mandates. This exemption is why two colleagues at the same company in different states might have different Wegovy coverage even though they carry the same employer insurance card.

Documenting Obesity as a Disease, Not a Lifestyle Choice

One of the most durable obstacles to Wegovy coverage approvals is the persistent framing of obesity as a behavioral failure rather than a chronic disease. The American Medical Association designated obesity as a disease in 2013. The American Heart Association, American College of Cardiology, and The Obesity Society 2013 guideline explicitly stated that obesity requires long-term medical management comparable to other chronic diseases [17].

Physicians writing prior-authorization letters or appeal documents should frame obesity using disease-state language, cite its specific ICD-10 code, reference the patient's comorbidity burden, and anchor the pharmacotherapy request to cardiovascular risk reduction data from SELECT rather than to weight loss alone. This framing shifts the clinical narrative from a cosmetic benefit to a medically necessary intervention for cardiovascular disease prevention.

The 2023 American Diabetes Association Standards of Care note: "Weight management is important for people with type 2 diabetes and those at risk for type 2 diabetes. Modest sustained weight loss in people with overweight or obesity can improve glycemia, blood pressure, and lipids and may reduce the need for medications to treat these conditions" [18].